What's Happening?
bioAffinity Technologies, Inc., a biotechnology company specializing in noninvasive diagnostics for lung cancer, has reported a substantial increase in the volume of its CyPath® Lung tests. The company announced that the number of tests processed in October
2025 was 111% higher than the monthly average for the year. This growth reflects a steady adoption of the test by physicians who recognize its clinical value in detecting lung cancer at early and treatable stages. The company has seen consistent month-over-month and quarter-over-quarter growth in test sales, with third-quarter sales volume increasing by 95% over the previous quarter. The CyPath® Lung test uses advanced flow cytometry and artificial intelligence to identify cancer-related cells in patient sputum, demonstrating high sensitivity, specificity, and accuracy in clinical studies.
Why It's Important?
The growth in CyPath® Lung test volume is significant as it indicates increasing trust and adoption among healthcare providers, potentially leading to improved early detection of lung cancer. Early diagnosis is crucial for effective treatment and can significantly enhance patient survival rates. The test's noninvasive nature and high accuracy make it a valuable tool in the diagnostic pathway for patients with indeterminate pulmonary nodules. As more physicians incorporate this test into their practice, it could shift the standard of care in lung cancer detection, offering a promising advancement in public health and potentially reducing healthcare costs associated with late-stage cancer treatments.
What's Next?
bioAffinity Technologies expects the upward trend in CyPath® Lung test sales to continue as more physicians adopt the test. The company is focused on expanding its outreach to pulmonologists, health systems, and VA medical centers to further increase adoption. Continued growth could lead to broader acceptance and integration of the test into standard diagnostic protocols, potentially influencing policy changes in lung cancer screening and treatment. The company may also explore further applications of its technology in other areas of cancer diagnostics.
Beyond the Headlines
The success of CyPath® Lung highlights the potential of artificial intelligence in medical diagnostics, offering a glimpse into the future of healthcare where AI-driven tools could become commonplace. This development raises ethical considerations regarding data privacy and the need for transparency in AI algorithms used in healthcare. Additionally, the test's noninvasive nature aligns with a broader trend towards less invasive medical procedures, which can improve patient comfort and compliance.
